Mitochondrial dysfunction in Alzheimer's disease - a proteomics perspective.


Journal

Expert review of proteomics
ISSN: 1744-8387
Titre abrégé: Expert Rev Proteomics
Pays: England
ID NLM: 101223548

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 21 4 2021
medline: 3 2 2022
entrez: 20 4 2021
Statut: ppublish

Résumé

Mitochondrial dysfunction is involved in Alzheimer's disease (AD) pathogenesis. Mitochondria have their own genetic material; however, most of their proteins (∼99%) are synthesized as precursors on cytosolic ribosomes, and then imported into the mitochondria. Therefore, exploring proteome changes in these organelles can yield valuable information and shed light on the molecular mechanisms underlying mitochondrial dysfunction in AD. Here, we review AD-associated mitochondrial changes including the effects of amyloid beta and tau protein accumulation on the mitochondrial proteome. We also discuss the relationship of ApoE genetic polymorphism with mitochondrial changes, and present a meta-analysis of various differentially expressed proteins in the mitochondria in AD.

Identifiants

pubmed: 33874826
doi: 10.1080/14789450.2021.1918550
doi:

Substances chimiques

Amyloid beta-Peptides 0
Proteome 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

295-304

Auteurs

Morteza Abyadeh (M)

Cell Science Research Center, Department of Molecular Systems Biology, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran Iran.

Vivek Gupta (V)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Nitin Chitranshi (N)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Veer Gupta (V)

School of Medicine, Deakin University, VIC, Australia.

Yunqi Wu (Y)

Australian Proteome Analysis Facility, Macquarie University, Macquarie Park, NSW Australia.

Danit Saks (D)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Roshana Wander Wall (R)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Matthew J Fitzhenry (MJ)

Australian Proteome Analysis Facility, Macquarie University, Macquarie Park, NSW Australia.

Devaraj Basavarajappa (D)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Yuyi You (Y)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Ghasem H Salekdeh (GH)

Department of Molecular Sciences, Macquarie University, Macquarie Park, NSW, Australia.

Paul A Haynes (PA)

Department of Molecular Sciences, Macquarie University, Macquarie Park, NSW, Australia.

Stuart L Graham (SL)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Mehdi Mirzaei (M)

Department of Clinical Medicine, Macquarie University, Macquarie Park, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH